--UCB, a global biopharmaceutical company, today announced that ZILBRYSQ ® has been approved by the U.S. Food and Drug Administration for the treatment of generalized myasthenia gravis in adult ...
Credit: Shutterstock. Zilbrysq is a complement inhibitor. The Food and Drug Administration (FDA) has approved Zilbrysq ® (zilucoplan) for the treatment of generalized myasthenia gravis (gMG) in adult ...
Zilbrysq is only available through a restricted program called Zilbrysq REMS. Zilbrysq ® (zilucoplan) is now available for the treatment of generalized myasthenia gravis (gMG) in adult patients who ...
ATLANTA, Jan. 3, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced today that ZILBRYSQ® (zilucoplan) is now available in the U.S. for the treatment of generalized myasthenia ...
UCB is on an approval roll. Within hours of each other, the Brussels-based company has scored FDA green lights for plaque psoriasis treatment Bimzelx and for generalized myasthenia gravis (gMG) drug ...
ATLANTA, Oct. 17, 2023 /PRNewswire/ -- UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that ZILBRYSQ ® (zilucoplan) has been approved by the U.S. Food and Drug ...
FDA approval of ZILBRYSQ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive1ZILBRYSQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback